A survey of the treatment of female patients with osteoporosis using drug utilization consumption parameters
Summary Objective: To investigate the drug treatment of female patients who were diagnosed with osteoporosis in South Africa using drug utilization consumption parameters. Method: Prescription data over a 2‐year period for 1655 female patients with osteoporosis were analysed retrospectively. Results...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 1999-06, Vol.24 (3), p.209-217 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 217 |
|---|---|
| container_issue | 3 |
| container_start_page | 209 |
| container_title | Journal of clinical pharmacy and therapeutics |
| container_volume | 24 |
| creator | Truter, I. Serfontein, J. H. P. |
| description | Summary
Objective: To investigate the drug treatment of female patients who were diagnosed with osteoporosis in South Africa using drug utilization consumption parameters.
Method: Prescription data over a 2‐year period for 1655 female patients with osteoporosis were analysed retrospectively.
Results: A total of 157 245 products at a cost of R15 004 643·51 was prescribed. Two‐thirds of the patients fell in the age group between 50 and 69 years. A quarter (25·33%) of the products prescribed were identified as products specifically for the treatment and/or prevention of osteoporosis. Calcium supplements were the most frequently prescribed therapeutic subgroup, followed by hormone replacement therapy. The most frequently prescribed product was an effervescent calcium supplement containing 500 mg elemental calcium. Alendronate 10 mg tablets accounted for the highest cost (23·57% of the total cost of products for osteoporosis), but accounted for only 7·36% of the number of products prescribed for osteoporosis. Prescribing differences were observed for patients younger than 50 years, and patients 50 years and older. The DU90% and DC90% segments consisted of 27 and 24 different trade name products, respectively.
Conclusion: Further studies focusing on the cost of osteoporosis treatment and prevention should be conducted incorporating clinical information |
| doi_str_mv | 10.1046/j.1365-2710.1999.00222.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69936538</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69936538</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5092-9183b70b6fd8edb5f1c1466e7bf4f2844f473af050177d09bda38961ea6aa9f3</originalsourceid><addsrcrecordid>eNqNkUtv1DAUhS0EokPhLyALIXYZ_EjseMGiGkEBVYBGI1haTmK3HpI4-EFn-PU4zaggVqx8df2de-1zAIAYrTEq2ev9GlNWFYTPDSHEGiFCyPrwAKzuLx6CFSJMFCUn_Aw8CWGPEGKc0MfgLA-hNa7xCvQXMCT_Ux-hMzDeaBi9VnHQY5wbRg-q13BS0eZOgLc23kAXonaT8y7YAFOw4zXsfLqGKdre_sqoG2HrxpCG6a6elFeDjtqHp-CRUX3Qz07nOdi9e7vbvC-uPl9-2FxcFW2FBCkErmnDUcNMV-uuqQxuccmY5o0pDanL0pScKoMqhDnvkGg6RWvBsFZMKWHoOXi1jJ28-5F0iHKwodV9r0btUpBMiGwSrTP44h9w75If89MkQagsWcVIhuoFavOPg9dGTt4Oyh8lRnJOQ-7lbLqcTZdzGvIuDXnI0uen-akZdPeXcLE_Ay9PgAqt6o1XY2vDH65miHOUsTcLdmt7ffzv_fLj5ssuV1lfLHqbozvc65X_LhmnvJLfPl1KSjbs63a7lYL-BnxJtkg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>200446562</pqid></control><display><type>article</type><title>A survey of the treatment of female patients with osteoporosis using drug utilization consumption parameters</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Truter, I. ; Serfontein, J. H. P.</creator><creatorcontrib>Truter, I. ; Serfontein, J. H. P.</creatorcontrib><description>Summary
Objective: To investigate the drug treatment of female patients who were diagnosed with osteoporosis in South Africa using drug utilization consumption parameters.
Method: Prescription data over a 2‐year period for 1655 female patients with osteoporosis were analysed retrospectively.
Results: A total of 157 245 products at a cost of R15 004 643·51 was prescribed. Two‐thirds of the patients fell in the age group between 50 and 69 years. A quarter (25·33%) of the products prescribed were identified as products specifically for the treatment and/or prevention of osteoporosis. Calcium supplements were the most frequently prescribed therapeutic subgroup, followed by hormone replacement therapy. The most frequently prescribed product was an effervescent calcium supplement containing 500 mg elemental calcium. Alendronate 10 mg tablets accounted for the highest cost (23·57% of the total cost of products for osteoporosis), but accounted for only 7·36% of the number of products prescribed for osteoporosis. Prescribing differences were observed for patients younger than 50 years, and patients 50 years and older. The DU90% and DC90% segments consisted of 27 and 24 different trade name products, respectively.
Conclusion: Further studies focusing on the cost of osteoporosis treatment and prevention should be conducted incorporating clinical information</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1046/j.1365-2710.1999.00222.x</identifier><identifier>PMID: 10438181</identifier><identifier>CODEN: JCPTED</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Aged ; Biological and medical sciences ; Bones, joints and connective tissue. Antiinflammatory agents ; Drug Costs ; Drug Prescriptions - economics ; Drug Utilization Review ; Female ; Humans ; Medical sciences ; Middle Aged ; Osteoporosis - drug therapy ; Osteoporosis - economics ; Pharmacology. Drug treatments ; Practice Patterns, Physicians ; South Africa</subject><ispartof>Journal of clinical pharmacy and therapeutics, 1999-06, Vol.24 (3), p.209-217</ispartof><rights>1999 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Jun 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5092-9183b70b6fd8edb5f1c1466e7bf4f2844f473af050177d09bda38961ea6aa9f3</citedby><cites>FETCH-LOGICAL-c5092-9183b70b6fd8edb5f1c1466e7bf4f2844f473af050177d09bda38961ea6aa9f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2710.1999.00222.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2710.1999.00222.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1860770$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10438181$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Truter, I.</creatorcontrib><creatorcontrib>Serfontein, J. H. P.</creatorcontrib><title>A survey of the treatment of female patients with osteoporosis using drug utilization consumption parameters</title><title>Journal of clinical pharmacy and therapeutics</title><addtitle>J Clin Pharm Ther</addtitle><description>Summary
Objective: To investigate the drug treatment of female patients who were diagnosed with osteoporosis in South Africa using drug utilization consumption parameters.
Method: Prescription data over a 2‐year period for 1655 female patients with osteoporosis were analysed retrospectively.
Results: A total of 157 245 products at a cost of R15 004 643·51 was prescribed. Two‐thirds of the patients fell in the age group between 50 and 69 years. A quarter (25·33%) of the products prescribed were identified as products specifically for the treatment and/or prevention of osteoporosis. Calcium supplements were the most frequently prescribed therapeutic subgroup, followed by hormone replacement therapy. The most frequently prescribed product was an effervescent calcium supplement containing 500 mg elemental calcium. Alendronate 10 mg tablets accounted for the highest cost (23·57% of the total cost of products for osteoporosis), but accounted for only 7·36% of the number of products prescribed for osteoporosis. Prescribing differences were observed for patients younger than 50 years, and patients 50 years and older. The DU90% and DC90% segments consisted of 27 and 24 different trade name products, respectively.
Conclusion: Further studies focusing on the cost of osteoporosis treatment and prevention should be conducted incorporating clinical information</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Drug Costs</subject><subject>Drug Prescriptions - economics</subject><subject>Drug Utilization Review</subject><subject>Female</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporosis - economics</subject><subject>Pharmacology. Drug treatments</subject><subject>Practice Patterns, Physicians</subject><subject>South Africa</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtv1DAUhS0EokPhLyALIXYZ_EjseMGiGkEBVYBGI1haTmK3HpI4-EFn-PU4zaggVqx8df2de-1zAIAYrTEq2ev9GlNWFYTPDSHEGiFCyPrwAKzuLx6CFSJMFCUn_Aw8CWGPEGKc0MfgLA-hNa7xCvQXMCT_Ux-hMzDeaBi9VnHQY5wbRg-q13BS0eZOgLc23kAXonaT8y7YAFOw4zXsfLqGKdre_sqoG2HrxpCG6a6elFeDjtqHp-CRUX3Qz07nOdi9e7vbvC-uPl9-2FxcFW2FBCkErmnDUcNMV-uuqQxuccmY5o0pDanL0pScKoMqhDnvkGg6RWvBsFZMKWHoOXi1jJ28-5F0iHKwodV9r0btUpBMiGwSrTP44h9w75If89MkQagsWcVIhuoFavOPg9dGTt4Oyh8lRnJOQ-7lbLqcTZdzGvIuDXnI0uen-akZdPeXcLE_Ay9PgAqt6o1XY2vDH65miHOUsTcLdmt7ffzv_fLj5ssuV1lfLHqbozvc65X_LhmnvJLfPl1KSjbs63a7lYL-BnxJtkg</recordid><startdate>199906</startdate><enddate>199906</enddate><creator>Truter, I.</creator><creator>Serfontein, J. H. P.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>199906</creationdate><title>A survey of the treatment of female patients with osteoporosis using drug utilization consumption parameters</title><author>Truter, I. ; Serfontein, J. H. P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5092-9183b70b6fd8edb5f1c1466e7bf4f2844f473af050177d09bda38961ea6aa9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Drug Costs</topic><topic>Drug Prescriptions - economics</topic><topic>Drug Utilization Review</topic><topic>Female</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporosis - economics</topic><topic>Pharmacology. Drug treatments</topic><topic>Practice Patterns, Physicians</topic><topic>South Africa</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Truter, I.</creatorcontrib><creatorcontrib>Serfontein, J. H. P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Truter, I.</au><au>Serfontein, J. H. P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A survey of the treatment of female patients with osteoporosis using drug utilization consumption parameters</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><addtitle>J Clin Pharm Ther</addtitle><date>1999-06</date><risdate>1999</risdate><volume>24</volume><issue>3</issue><spage>209</spage><epage>217</epage><pages>209-217</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><coden>JCPTED</coden><abstract>Summary
Objective: To investigate the drug treatment of female patients who were diagnosed with osteoporosis in South Africa using drug utilization consumption parameters.
Method: Prescription data over a 2‐year period for 1655 female patients with osteoporosis were analysed retrospectively.
Results: A total of 157 245 products at a cost of R15 004 643·51 was prescribed. Two‐thirds of the patients fell in the age group between 50 and 69 years. A quarter (25·33%) of the products prescribed were identified as products specifically for the treatment and/or prevention of osteoporosis. Calcium supplements were the most frequently prescribed therapeutic subgroup, followed by hormone replacement therapy. The most frequently prescribed product was an effervescent calcium supplement containing 500 mg elemental calcium. Alendronate 10 mg tablets accounted for the highest cost (23·57% of the total cost of products for osteoporosis), but accounted for only 7·36% of the number of products prescribed for osteoporosis. Prescribing differences were observed for patients younger than 50 years, and patients 50 years and older. The DU90% and DC90% segments consisted of 27 and 24 different trade name products, respectively.
Conclusion: Further studies focusing on the cost of osteoporosis treatment and prevention should be conducted incorporating clinical information</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>10438181</pmid><doi>10.1046/j.1365-2710.1999.00222.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-4727 |
| ispartof | Journal of clinical pharmacy and therapeutics, 1999-06, Vol.24 (3), p.209-217 |
| issn | 0269-4727 1365-2710 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69936538 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Drug Costs Drug Prescriptions - economics Drug Utilization Review Female Humans Medical sciences Middle Aged Osteoporosis - drug therapy Osteoporosis - economics Pharmacology. Drug treatments Practice Patterns, Physicians South Africa |
| title | A survey of the treatment of female patients with osteoporosis using drug utilization consumption parameters |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T18%3A19%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20survey%20of%20the%20treatment%20of%20female%20patients%20with%20osteoporosis%20using%20drug%20utilization%20consumption%20parameters&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Truter,%20I.&rft.date=1999-06&rft.volume=24&rft.issue=3&rft.spage=209&rft.epage=217&rft.pages=209-217&rft.issn=0269-4727&rft.eissn=1365-2710&rft.coden=JCPTED&rft_id=info:doi/10.1046/j.1365-2710.1999.00222.x&rft_dat=%3Cproquest_cross%3E69936538%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=200446562&rft_id=info:pmid/10438181&rfr_iscdi=true |